Æ÷À¯·ù ´ÙŬ·Ð IgG Ç×ü ½ÃÀå º¸°í¼­ : À¯Çü, Á¦Ç°, ¿ëµµ, ÃÖÁ¾ ¿ëµµ, Áö¿ªº°(2025-2033³â)
Mammalian Polyclonal IgG Antibody Market Report by Type, Product, Application, End Use, and Region 2025-2033
»óǰÄÚµå : 1753919
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 138 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,355,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,808,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 7,260,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Æ÷À¯·ù ´ÙŬ·Ð IgG Ç×ü ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 11¾ï 4,180¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ÀÌ ½ÃÀåÀÌ 2033³â±îÁö 17¾ï 260¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2025-2033³â±îÁö 4.31%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î Àü¸ÁÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ¿¬±¸±â°ü°ú »ê¾÷ü¿ÍÀÇ °øµ¿ ¿¬±¸ Áõ°¡, ´ÜŬ·ÐÇ×ü ¹× ´ÙŬ·ÐÇ×ü ¿¬±¸¿¡ ´ëÇÑ °ü½É Áõ°¡, ¼¼°è ÇコÄɾî ÀÎÇÁ¶ó È®´ë, ÀÚ°¡¸é¿ªÁúȯ Ä¡·á¿¡¼­ÀÇ »ç¿ë Áõ°¡, ÀçÁ¶ÇÕ Ç×ü ä¿ë È®´ë, CRO(ÀǾàǰ °³¹ß ¼öʱâ°ü) »ê¾÷ÀÇ °ý¸ñÇÒ¸¸ÇÑ ¼ºÀå µîÀÔ´Ï´Ù. ¼ºÀå µîÀÌ ÀÖ½À´Ï´Ù.

Æ÷À¯·ù Æú¸®Å¬·Î³¯ ¸é¿ª±Û·ÎºÒ¸°(IgG) Ç×ü´Â ¸¶¿ì½º, Åä³¢, ¿°¼Ò µî ´Ù¾çÇÑ Æ÷À¯·ù¿¡ Ç׿øÀ» Á¢Á¾ÇÏ¿© Á¦Á¶µÇ´Â Ç׿øÀ̳ª ¿¹¹æÁ¢Á¾À» ¸»ÇÕ´Ï´Ù. ÀÌ ¹æ¹ý¿¡¼­´Â IgG¸¦ °ø±ÞÇÏ´Â B¸²ÇÁ±¸¸¦ Ȱ¼ºÈ­½Ã۱â À§ÇØ Æ÷À¯µ¿¹°ÀÇ Ã¼³»¿¡ Ç׿øÀ» ÁÖ»ç·Î Åõ¿©ÇÕ´Ï´Ù. ÀÌ Ç×ü´Â È¿¼Ò °áÇÕ ¸é¿ª ÈíÂø ÃøÁ¤¹ý(ELISA), ¿þ½ºÅÏ ºí·Ô °Ë»ç, ¸é¿ª ¹æ»ç´É ÃøÁ¤¹ý(IRMA), ¹æ»ç¼± ¸é¿ªºÐ¼®¹ý(RIA) µî ¿©·¯ ¸é¿ªÃøÁ¤ °Ë»ç¿¡¼­ Ç¥Áö ½Ã¾àÀ¸·Î »ç¿ëµË´Ï´Ù. ÀÌ ¿Ü¿¡µµ ÀÌ °øÁ¤Àº ¼÷·ÃµÈ Àü¹®°¡¸¦ ÇÊ¿ä·Î ÇÏÁö ¾ÊÀ¸¸ç, ´ë·®ÀÇ ¿¹¹æÁ¢Á¾À» »ý»êÇÒ ¼ö ÀÖ½À´Ï´Ù. Æ÷À¯·ù ´ÙŬ·Ð IgG Ç×ü´Â ¿©·¯ Ä¡·á¹ýÀ» ¸¸µé°í, ´Ù¾çÇÑ Áúº´À» Áø´ÜÇϰí, Ç×ü¸¦ ½Äº°Çϰí, À¯¼¼Æ÷ ºÐ¼®À» ¼öÇàÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ±× °á°ú, »ýÈ­ÇÐ ¿¬±¸¿¡¼­ º¯¼º ´Ü¹éÁúÀÇ °ËÃâ, Áúº´°ú ±× Ä¡·á¹ý Á¶»ç µî ±¤¹üÀ§ÇÑ ¿ëµµ°¡ ¹ß°ßµÇ°í ÀÖ½À´Ï´Ù. ÇöÀç ½ÉÀå ¸¶Ä¿, ´ë»ç ¸¶Ä¿, ½ÅÀå ¸¶Ä¿ÀÇ Á¦Ç° º¯ÇüÀÌ ½ÃÆÇµÇ°í ÀÖ½À´Ï´Ù.

Æ÷À¯·ù ´ÙŬ·Ð IgG Ç×ü ½ÃÀå µ¿Çâ

¸¸¼ºÁúȯ Áõ°¡

¾Ï, ½ÉÇ÷°üÁúȯ, ÀÚ°¡¸é¿ªÁúȯ µî ¸¸¼ºÁúȯÀÇ Áõ°¡´Â Æ÷À¯·ù ´ÙŬ·Ð IgG Ç×ü ½ÃÀå ±Ô¸ð È®´ëÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ÀÏ¹Ý Å¬¸®´Ð¿¡¼­ 28°³ÀÇ Áø´Ü ±â·Ï¿¡ µû¸¥ 25¼¼ ÀÌ»ó ¸¸¼ºÁúȯÀ» Çϳª ÀÌ»ó ¾Î°í ÀÖ´Â À¯º´·üÀº 2004³â 34.9%¿¡¼­ 2011³â 41.8%·Î Áõ°¡ÇßÀ¸¸ç, ÀÌ ±â°£ µ¿¾È 6.9% Æ÷ÀÎÆ®ÀÇ Åë°èÀûÀ¸·Î À¯ÀǹÌÇÑ Áõ°¡¸¦ º¸¿´½À´Ï´Ù. ÀÌ·¯ÇÑ Áúº´Àº º¸´Ù Áøº¸µÈ Áø´Ü°ú °ü¸®°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ Æ÷À¯·ù ´ÙŬ·Ð IgG Ç×ü´Â ÀϹÝÀûÀ¸·Î ¸é¿ª ÃøÁ¤, ¹æÇ⼺ Ä¡·á, ¸é¿ª ü°è Á¶Àý¿¡ »ç¿ëµË´Ï´Ù. ¸¸¼ºÁúȯÀÇ Áö¼ÓÀûÀÎ Áõ°¡·Î ÀÎÇØ Ç×ü¸¦ ±â¹ÝÀ¸·Î ÇÑ »ó´ëÀû ¼Ö·ç¼Ç ¹× ±âŸ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀåÀÇ Ãß°¡ ¹ßÀü¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

Ä¡·á¿ë Ç×ü¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡

Ä¡·á¿ë Ç×ü¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â Æ÷À¯·ù ´ÙŬ·Ð IgG Ç×ü ½ÃÀå Á¡À¯À²À» È®´ëÇÏ´Â Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù. Ä¡·á¿ë Ç×ü´Â ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, °¨¿°¼º Áúȯ µî ´Ù¾çÇÑ ÁúȯÀÇ Ä¡·á¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À Á¦¾à»çµéÀÌ Ç×ü ±â¹Ý Ä¡·á¹ýÀ» °³¹ßÇÔ¿¡ µû¶ó ¸é¿ª ¹ÝÀÀ Á¶Àý ¹× ¿¬±¸¿ëÀ¸·Î ÇʼöÀûÀÎ Æú¸®Å¬·Î³¯ IgG Ç×ü¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ç×ü °øÇÐÀÇ ¹ßÀü°ú ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ Ä¡·á¿ë Ç×üÀÇ Ã¤ÅÃÀÌ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¿ä Áõ°¡´Â Æ÷À¯·ù ´ÙŬ·Ð IgG Ç×üÀÇ ¿¬±¸, °³¹ß ¹× »ý»êÀ» ÃËÁøÇϰí, ½ÃÀå ¼ºÀå°ú Çö´ë ÀÇ·á ºÐ¾ßÀÇ ÀÀ¿ë ºÐ¾ß È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

»ý¸í°øÇÐ ¹× Á¦¾à »ê¾÷ÀÇ °ý¸ñÇÒ¸¸ÇÑ ¼ºÀå

»ý¸í°øÇÐ ¹× Á¦¾à »ê¾÷ÀÇ ¼ºÀåÀº ½ÃÀåÀÇ Áß¿äÇÑ ÃËÁøÁ¦ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ »ê¾÷ÀÇ È®Àå°ú ÇÔ²² Çõ½ÅÀûÀÎ Ä¡·á ¹× Áø´Ü ¼Ö·ç¼Ç°ú °ü·ÃµÈ ¿¬±¸°³¹ß(R&D) Ȱµ¿¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Æú¸®Å¬·Î³¯ IgG Ç×ü´Â ƯÈ÷ ¾ÏÀ̳ª ÀÚ°¡¸é¿ªÁúȯ°ú °°Àº º¹ÀâÇÑ Áúº´¿¡ ´ëÇÑ ½Å¾à°³¹ß, Áúº´ Áø´Ü ¹× Ä¡·á¹ý °³¹ß¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Ç×ü°øÇаú °°Àº ¹ÙÀÌ¿ÀÀǾàǰ ±â¼úÀÇ Áö¼ÓÀûÀÎ ¹ßÀü°ú »ý¹°ÇÐÀû Á¦Á¦ ¹× ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ ÃßÁø ¶ÇÇÑ ÀÌ·¯ÇÑ Ç×üÀÇ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖÀ¸¸ç, ÀÌ´Â Ç×üÀÇ »ý»ê·® Áõ°¡¿Í ¿ëµµ È®´ë·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸ÂÃãÀÇ·á¿Í Á¤¹ÐÄ¡·á¿¡ ´ëÇÑ ¾÷°èÀÇ °ü½ÉÀº °íǰÁú Ç×üÀÇ Çʿ伺À» Áõ°¡½ÃÄÑ ½ÃÀåÀ» ´õ¿í Ȱ¼ºÈ­½Ã۰í ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

Á¦5Àå ¼¼°èÀÇ Æ÷À¯·ù ´ÙŬ·Ð IgG Ç×ü ½ÃÀå

Á¦6Àå ½ÃÀå ³»¿ª : À¯Çüº°

Á¦7Àå ½ÃÀå ³»¿ª : Á¦Ç°º°

Á¦8Àå ½ÃÀå ³»¿ª : ¿ëµµº°

Á¦9Àå ½ÃÀå ³»¿ª : ÃÖÁ¾ ¿ëµµº°

Á¦10Àå ½ÃÀå ³»¿ª : Áö¿ªº°

Á¦11Àå SWOT ºÐ¼®

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå Porter's Five Forces ºÐ¼®

Á¦14Àå °¡°Ý ºÐ¼®

Á¦15Àå °æÀï ±¸µµ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global mammalian polyclonal IgG antibody market size reached USD 1,141.8 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,702.6 Million by 2033, exhibiting a growth rate (CAGR) of 4.31% during 2025-2033. The market growth is driven by the increasing collaborations between research institutes and industry players, the rising focus on monoclonal and polyclonal antibody research, the expanding global healthcare infrastructure, the growing use in autoimmune disease treatment, the escalating adoption of recombinant antibodies, and significant growth of the contract research organization (CRO) industry.

Mammalian polyclonal immunoglobulins (IgG) antibody refers to antigens or vaccinations that are manufactured through inoculation of various mammals, including mice, rabbits, and goats. During this procedure, an antigen is administered via injectable into the mammal body to activate the B-lymphocytes that supply IgG. These antibodies are used in labeling reagents in multiple immunoassay tests, including enzyme-linked immunosorbent assay (ELISA), western blot tests, immunoradiometric assay (IRMA), and radioimmunoassay (RIA). Apart from this, the process does not require skilled professionals to produce large batches of vaccinations. Mammalian polyclonal IgG antibody helps create multiple therapeutics, diagnose various ailments, and perform antibody identification and flow cytometry. As a result, they find extensive applications in biochemical research to detect denatured proteins and examine diseases and their treatments. At present, they are commercially available in cardiac, metabolic, and renal marker product variants.

Mammalian Polyclonal IgG Antibody Market Trends:

Increasing prevalence of chronic diseases

The increasing number of cases of chronic diseases, such as cancer, cardiovascular disease, and autoimmune diseases, is a major factor leading to the expansion of the mammalian polyclonal IgG antibody market size. For instance, the prevalence of individuals aged 25 and older with at least one chronic disease, based on 28 recorded diagnoses in general practice, rose from 34.9% in 2004 to 41.8% in 2011, reflecting a statistically significant increase of 6.9 percentage points during that period. As these conditions require more sophisticated diagnostics and management, mammalian polyclonal IgG antibodies are commonly used in immunoassays, directed therapy, and modulation of the immune system. Due to the persistent growth in chronic medical conditions, the prevalent need for relative antibody-based and other solutions contributes to the further advancement of the market.

Rising demand for therapeutic antibodies

The rising demand for therapeutic antibodies is a key factor augmenting the mammalian polyclonal IgG antibody market share. Therapeutic antibodies are increasingly used in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases, due to their high specificity and ability to target disease-causing agents effectively. As biopharmaceutical companies develop more antibody-based therapies, the demand for polyclonal IgG antibodies, which are essential in immune response modulation and research applications, is growing. Additionally, advancements in antibody engineering and an increased focus on personalized medicine further enhance the adoption of therapeutic antibodies. This rising demand fuels research, development, and production of mammalian polyclonal IgG antibodies, contributing to significant market growth and expanding their applications in modern healthcare.

Significant growth in the biotechnology and pharmaceutical industries

The growth of the biotechnology and pharmaceutical industries is a significant driver of the market. As these industries expand, there has been increasing investments in research and development (R&D) activities involving innovative therapeutic and diagnostic solutions. Polyclonal IgG antibodies play a critical role in drug discovery, disease diagnostics, and therapeutic development, especially for complex diseases like cancer and autoimmune disorders. Continual advancements in biopharmaceutical technologies, such as antibody engineering, and the push for biologics and biosimilars are also driving the demand for these antibodies, leading to increased production and wider applications for these antibodies. Additionally, the industry's focus on personalized medicine and precision therapies increases the need for high-quality antibodies, further providing a boost to the market.

Key Market Segmentation:

Breakup by Type:

Breakup by Product:

Breakup by Application:

Breakup by End Use:

Breakup by Region:

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global mammalian polyclonal IgG antibody market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:

Key Questions Answered in This Report

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Mammalian Polyclonal IgG Antibody Market

6 Market Breakup by Type

7 Market Breakup by Product

8 Market Breakup by Application

9 Market Breakup by End Use

10 Market Breakup by Region

11 SWOT Analysis

12 Value Chain Analysis

13 Porters Five Forces Analysis

14 Price Analysis

15 Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â